Loading
Latest filing published 02 Sept 2026 for Innovent Biologics, Inc..
No signal scores available.
Not enough history yet: 0 closed purchases, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Cooney Charles Leland appears as a Director at Innovent Biologics, Inc., a company listed on the Hong Kong stock exchange, in 13 filings published between November 13, 2018 and September 2, 2026. The record holds 8 purchases, 2 sales and 3 filings of another kind, with no grant or option exercise. Purchases make up 80% of market trades.
The only sale with a recorded amount is dated August 27, 2026: EUR 456,203. It is among the three filings of the last twelve months, which also include a purchase. Publication takes longer here than usual: a median of 6 days, across 12 dated filings.
Over the period the yearly count of filings is between 1 and 3, with a maximum of 3 in 2026.
Trades by Leland within 30 days of colleagues at Innovent Biologics, Inc. number 9, 9 and 8. Same direction: 9, 8 and 8. Names in order: Hsu Joyce I-Yin, Ede Ronald Hao Xi and Yu De-Chao Michael.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
13 of 13 declarations